Table 4.
Treatment | 3 month |
6 month |
9 month |
|||
---|---|---|---|---|---|---|
n | Average # (days) | n | Average # (days) | n | Average # (days) | |
Vehicle | 37 | 22.02 ± 0.22 | 29 | 23.85 ± 0.71 | 21 | 23.30 ± 0.80 |
25 ng BPA | 25 | 22.49 ± 0.35 | 26 | 21.96 ± 0.22 | 16 | 23.14 ± 0.70 |
250 ng BPA | 33 | 22.47 ± 0.22 | 27 | 23.61 ± 0.57 | 16 | 28.75 ± 1.31a,b |
25 μg BPA | 30 | 21.74 ± 0.18 | 26 | 22.70 ± 0.40 | 18 | 27.14 ± 2.33a |
10 ng DES | 29 | 22.34 ± 0.27 | 27 | 23.63 ± 1.33 | 20 | 25.50 ± 1.19b |
Different from controls at 9 months (p < 0.05).
Different from females exposed to same treatment at 3 months of age (p < 0.05; ANOVA).